Last update April 16, 2024

Spirapril Hydrochloride

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Spirapril and its active metabolite spiraprilat are angiotensin converting enzyme inhibitors (ACEI) used in the treatment of hypertension. Oral administration once day.

At the time of the last update, we found no published data on its excretion in breast milk.

Other compounds in the same group (ACEI) are not significantly excreted in breast milk, but until further published data on this drug in relation to breastfeeding are known safer alternatives may be preferable. (Anderson 2018)

Due to its potential renal toxicity in premature infants, it is preferable to avoid its use during the neonatal period in case of prematurity. (Serrano 2015)

The protective role of breastfeeding against maternal hypertension has been proven. (Park 2018)

Alternatives

  • Captopril (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Spirapril Hydrochloride in other languages or writings:

Groups

Spirapril Hydrochloride belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Spirapril Hydrochloride in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 45 - 50 %
Molecular weight 503 daltons
Protein Binding 89 %
VD 0.4 - 0.6 l/Kg
pKa 3.62 -
Tmax 2 - 3 hours
T½ 30 - 35 hours

References

  1. Park S, Choi NK. Breastfeeding and Maternal Hypertension. Am J Hypertens. 2018 Abstract
  2. Anderson PO. Treating Hypertension During Breastfeeding. Breastfeed Med. 2018 Abstract
  3. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Jan 20;144(2):73-9. Abstract
  4. Grass P, Gerbeau C, Kutz K. Spirapril: pharmacokinetic properties and drug interactions. Blood Press Suppl. 1994 Abstract

Total visits

3,557

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche, España of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM